A new treatment for osteoporosis in postmenopausal women at high risk of fracture
The US Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
To continue reading this article
Continue reading your article with a eMediNexus account.